Table 2.

Concomitant Genetic Alterations in ROS1-Rearranged NSCLC.

Patient	Genes with Alterations	Prior Systemic Therapya
1	ATM, CTNNB1, TP53, DNMT3A	Yes
2	TP53	No
6	TP53	No
10	TP53	No
14	TP53, SMAD4, APC	No
24	TP53, ROS1 (p.G2032R)	Yesb
42	MAP2K4, SF3B1	No
43	TP53	Yes
45	TSC2	No
46	TP53	No
48	KRAS (p.I24N), CTNNB1, TP53	No
49	BAP1, CHEK2	No
50	CTNNB1	Yes
53c	KRAS (p.G13D), EGFR (p.C781F), KIT, IDH1	No
54	CDKN2A, TP53	No
55	FLT1, PRKDC, RUNX1	No
57	TP53	No
59	CCND1, ARID1A, CDKN2A/B, FGF19, FGF4, FGF3	No
60	MSH6, CDKN2A	No
61	CDKN2A/B	No

^aPrior systemic therapy includes chemotherapy and/or crizotinib.

^bThis tumor sample was derived post-crizotinib. The pre-crizotinib tumor sample did not harbor the ROS1 G2032R mutation, which is a known crizotinib-resistant mutation.²³

^cThis tumor sample tested positive for ROS1 rearrangement by FISH, but targeted RNA sequencing did not detect a ROS1 fusion transcript.